📰 The July 3 issue of Neurology Today is live! Featuring stories on the new Alzheimer’s blood test, research funding cuts, fremanezumab’s benefit for depression & migraine, and more. Catch the recap on Neurology Today in 5! 🎧 @BrainHealthMD @AANMember.

📚 What makes a great peer reviewer? Dr. Jose Merino of @GreenJournal and others share insights from the editorial front lines. @beckerbarroso @AANMember #NeuroTwitter.

🧬 Anti-retrovirals may lower Alzheimer’s risk, says Dr. Jayakrishna Ambati of @UVA. Promising data, more research needed. @AANMember #NeuroTwitter.

🧠 Shingles vaccine may cut dementia risk by 20%, says Dr. Pascal Geldsetzer of @StanfordMed. A simple shot, big impact. @PGeldsetzer1 @AANMember #NeuroTwitter.

💊 Fremanezumab reduces both migraine & depression symptoms, says Dr. Richard B. Lipton of @EinsteinMed. A promising dual benefit. @DawnBuse @AANMember #NeuroTwitter.

🛌 Longer time in bed post-stroke may signal small vessel disease risk, says Dr. Dillys Xiaodi Liu of @UCSF. Sleep data could be key in stroke care. @phx_ua @AANMember #NeuroTwitter.

🧬 Healthy lifestyle choices may offset the brain risks of shortened telomeres, says Dr. Christopher D. Anderson of Harvard. A hopeful step for stroke, dementia & depression prevention. @CDAndersonMD @AANMember #NeuroTwitter.

Neurology Today wishes you a safe and happy Independence Day!

💸 Federal research cuts are reshaping academic neurology. Leaders like Dr. Jeste say institutions must adapt to protect early-career researchers. @gordonsmithMD @ChildrensLA @AANMember #NeuroTwitter.

🧪 The FDA’s approval of a blood test for Alzheimer’s offers promise—but also raises concerns about misuse and misinterpretation. Experts urge education and caution. @RenegadeSynapse @WakeForestMed @AANMember #NeuroTwitter.

Don’t miss the June 19 issue of Neurology Today—featuring AI in neuro drug discovery, prenatal triptan safety & Alzheimer’s-like biomarkers in non-AD dementias. 🎧 Listen to the recap on Neurology Today in 5. @BrainHealthMD @AANMember #NeuroTwitter.

🧠 How should neurologists talk about novel or off-label therapies? AAN’s new statement offers guidance grounded in evidence, ethics & shared decision-making. Read more from @LBGoldsteinMD. @UKYMedicine. @AANMember #NeuroTwitter.

Medical therapy alone matched revascularization + meds for low-risk carotid stenosis in a new trial. Experts weigh in on study design and clinical impact. @ChaturvediNeuro @AANMember #NeuroTwitter.

🧬 New meta-analysis confirms AD-like pathology in non-AD dementias. Experts stress the clinical importance as amyloid-clearing therapies make early detection key. @HinmanLabUCLA @uniofgothenburg @AANMember #NeuroTwitter.

AI is mining big data to repurpose drugs. Early wins in blood disorders, and now hypothesis-generating candidates are emerging for Parkinson’s & Alzheimer’s. @FeixiongCheng @AANMember #NeuroTwitter.

🌍 New study finds fewer ischemic strokes in areas with reduced air pollution—adding to growing evidence linking air quality and stroke risk. @TempleCPH @AANMember #NeuroTwitter.

🧠 A small trial found lowering BP to <140 mmHg after ICH is safe and doesn't increase ischemic lesions on MRI. Experts urge more research to understand lesion development. @jrmbernstein @AANMember #NeuroTwitter.

A Norwegian meta-analysis found no link between prenatal triptan exposure & neurodevelopmental disorders. Experts say findings are reassuring but more trimester-specific data is needed. @HartfordHealthC @AANMember #NeuroTwitter.

🧬 The AAN Guidelines Subcommittee reviewed gene therapy for #DuchenneMuscularDystrophy, citing efficacy, safety, cost concerns & research gaps. Full story in Neurology Today. @FrizzanteNY @AANMember #NeuroTwitter.

📰 The June 19 issue of Neurology Today is live, featuring stories on AI-driven drug discovery for neurodegenerative diseases, the safety of prenatal triptan exposure, and Alzheimer’s-like biomarkers in non-AD dementias. @BrainHealthMD @AANMember.